2022-10-20| In-DepthSpecial

Leveraging Synthetic Biology, Microbiome-based Therapies Open Up Possibilities for Clinical Applications

by GeneOnline
Share To
Among all areas of development in synthetic biology, microbiome therapy is one of the most rapidly advancing and highly anticipated areas of technology. As the science community uncovers the close relationship between microbial ecology and human health, microbiomes are regarded as a “second genome” apart from the human genome, with extensive effects on gastrointestinal health, chronic diseases, cancer, and psychological disorders. As a result, clinical applications of microorganisms are becoming increasingly prevalent, ranging from therapeutics, diagnostics,  disease prevention, and novel carriers of therapeutic molecules. Companies and institutions are testing these in clinical trials, and regulatory agencies have approved some for marketing as derivative pharmaceutical products. With the main focus on microbiome therapy, this feature article will provide an in-depth overview of this promising technology's technical principles, clinical applications, and future trends.

GO Prime with only $1.49 now

35% Of Better Therapeutics’ Staff to be Cut to Extend the Company’s Runway
Pharming’s Joenja Racks Up FDA Approval For Rare Primary Immunodeficiency
Ways to Reduce Carbon Emission in Cement Manufacturing
Moderna Injects $76 Million To Kickstart Lipid Nanoparticle Delivery Partnership With Generation Bio
Shining a Light on Oncology with Rakuten Medical Co-CEO Takashi Toraishi
Incyte’s Zynyz Secures FDA Approval for Treating a Rare and Aggressive Skin Cancer
Biohaven Licenses TYK2/JAK1 Dual Inhibitor From China’s Highlight In $970 Million Pact
Scroll to Top